PLX : Insider Transactions for Protalix Biotherapeutics | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Protalix Biotherapeutics (PLX)

$0.26 0.00 (0.00%) as of 4:30 Fri 2/14

Download

Exchange:

American Stock Exchange

Security Type:

Common

Shares Out:

45,560,000

Market Cap:

12.06(M)

Last Volume:

1,167,076

Avg Vol:

536,427

52 Week Range:

$0.2646 - $0.2646

Level I Sector:

Health Care

Level II Sector:

Drugs

Level III Sector:

Biotechnology

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : -

Guru Rank Value : -

Guru Occurances : -


6 Months 1 Year 2 Year

Company Profile Protalix BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system. Co.'s proprietary ProCellEx platform is being used to manufacture its marketed product, Elelyso®, for the treatment of Gaucher disease. Co. is also developing, via ProCellEx, a pipeline of products. Co.'s clinical development program for pegunigalsidase alfa, or PRX-102, for the potential treatment of Fabry disease. In addition, Co. is developing uricase, or PRX-115, for the treatment of refractory gout.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	64,516	174,516
Total Buy Value	$0	$0	$90,484	$246,299
Total People Bought	0	0	1	2
Total Buy Transactions	0	0	1	2
Total Shares Sold	0	0	0	0
Total Sell Value	$0	$0	$0	$0
Total People Sold	0	0	0	0
Total Sell Transactions	0	0	0	0
End Date	2024-02-18	2023-11-17	2023-05-19	2022-05-19

Adjust Filter Settings

Records found: 182

Page 4 of 8

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

CEO and President

• • –

2009-10-20

4

AS

$9.45

$567,000

I/I

(60,000)

0

-

CEO and President

• • –

2009-10-19

4

AS

$9.43

$1,414,500

I/I

(150,000)

0

-

Shaaltiel Yoseph

Executive VP, R&D

• • –

2009-10-19

4

AS

$9.43

$406,622

D/D

(43,120)

1,263,754

-

Almon Einat Brill

VP, Product Development

• – –

2009-10-19

4

D

$9.48

$37,484

I/I

(3,954)

0

-

Almon Einat Brill

VP, Product Development

• – –

2009-10-19

4

OE

$0.40

$37,488

I/I

93,954

0

-

Almon Einat Brill

VP, Product Development

• – –

2009-10-19

4

AS

$9.43

$361,358

I/I

(38,320)

0

-

Shaaltiel Yoseph

Executive VP, R&D

• • –

2009-10-16

4

AS

$9.39

$241,135

D/D

(25,680)

1,306,874

-

Almon Einat Brill

VP, Product Development

• – –

2009-10-16

4

AS

$9.39

$222,355

I/I

(23,680)

0

-

VP, Chief Financial Officer

• – –

2009-10-16

4

D

$9.21

$162,999

I/I

(17,698)

0

-

VP, Chief Financial Officer

• – –

2009-10-16

4

OE

$0.97

$163,002

I/I

167,698

0

-

VP, Chief Financial Officer

• – –

2009-10-16

4

AS

$9.35

$376,805

I/I

(40,300)

0

-

Shaaltiel Yoseph

Executive VP, R&D

• • –

2009-10-15

4

AS

$9.39

$292,968

D/D

(31,200)

1,332,554

-

Almon Einat Brill

VP, Product Development

• – –

2009-10-15

4

AS

$9.39

$262,920

I/I

(28,000)

0

-

VP, Chief Financial Officer

• – –

2009-10-15

4

AS

$9.50

$1,042,150

I/I

(109,700)

0

-

Frost Gamma Investment Trust

10% Owner

– – •

2009-09-10

4

S

$7.35

$952,190

I/I

(128,074)

7,610,167

-

Frost Gamma Investment Trust

10% Owner

– – •

2009-09-09

4

S

$7.52

$377,509

I/I

(50,000)

7,738,241

-

Frost Gamma Investment Trust

10% Owner

– – •

2009-08-28

4

S

$6.00

$163,860

I/I

(27,307)

7,863,241

-

Frost Gamma Investment Trust

10% Owner

– – •

2009-08-27

4

S

$6.00

$240,599

I/I

(40,000)

7,890,548

-

Frost Gamma Investment Trust

10% Owner

– – •

2009-08-26

4

S

$6.02

$304,010

I/I

(50,000)

7,930,548

-

Frost Gamma Investment Trust

10% Owner

– – •

2009-08-25

4

S

$6.00

$2,324,700

I/I

(383,500)

7,985,048

-

Frost Gamma Investment Trust

10% Owner

– – •

2009-08-25

4

S

$6.37

$28,767

I/I

(4,500)

7,980,548

-

Frost Gamma Investment Trust

10% Owner

– – •

2009-08-24

4

S

$6.00

$898,832

I/I

(148,365)

8,368,548

-

Frost Gamma Investment Trust

10% Owner

– – •

2009-08-21

4

S

$6.08

$91,364

I/I

(15,000)

8,516,913

-

Frost Gamma Investment Trust

10% Owner

– – •

2009-08-20

4

S

$6.05

$609,323

I/I

(100,000)

8,531,913

-

Frost Gamma Investment Trust

10% Owner

– – •

2009-08-19

4

S

$6.10

$611,642

I/I

(100,000)

8,631,913

-

182 Records found	1 2 3 4 5 6 7 8	Page 4 of 8

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.